PharmGKB and Pharmacogenomics Resources

  • Pharmacogenomics is the study of how genetic variation influences an individual’s response to medicines. Genetic differences can affect drug absorption, distribution, metabolism, elimination, transport, and interaction with biological targets. These differences may influence treatment effectiveness, required dosage, adverse drug reactions, and the risk of treatment failure. Pharmacogenomics combines genetics, molecular biology, pharmacology, clinical medicine, and bioinformatics to support more precise and individualized drug therapy. It is an important component of precision medicine because it helps explain why the same medication and dose may produce different outcomes in different individuals.
  • Drug response is influenced by several factors, including genetic variation, age, sex, body composition, kidney and liver function, other medications, diet, environmental exposures, and disease characteristics. Genetic variation is therefore one part of a broader clinical picture. Pharmacogenomic research investigates how variants in genes encoding drug-metabolizing enzymes, transporters, receptors, and other proteins contribute to differences in drug response. Some variants reduce enzyme activity, while others increase activity, alter protein expression, or produce proteins with different functional properties. The resulting changes may influence drug concentrations, active metabolite formation, therapeutic effects, and toxicity.
  • The Pharmacogenomics Knowledgebase (PharmGKB) was established as a major resource for collecting, curating, and disseminating information about the relationships between human genetic variation and drug response. It brought together pharmacogenomic findings from scientific literature, clinical guidelines, regulatory drug labels, and other authoritative sources. Its content included gene–drug associations, variant annotations, clinical annotations, drug-centred pathways, pharmacogenomic summaries, and prescribing recommendations. PharmGKB became an important knowledge resource for researchers, clinicians, pharmacologists, and bioinformaticians working in pharmacogenomics.
  • An important development in the resource landscape occurred in July 2025, when ClinPGx replaced the standalone PharmGKB website as the integrated portal for clinical pharmacogenomics knowledge. ClinPGx brings together the PharmGKB knowledgebase, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, and the Pharmacogenomic Clinical Annotation Tool (PharmCAT) resources under one platform. The historical PharmGKB name remains important in publications, database identifiers, and data provenance, but users seeking the current portal and downloads should use ClinPGx. <Cite refs={[“turn417995search1″,”turn417995search10″,”turn417995search2”]}/>
  • ClinPGx provides several types of pharmacogenomic information. Clinical annotations summarize evidence connecting genetic variation with drug response or clinical outcomes. Variant annotations describe the relationships between specific variants and pharmacogenomic phenotypes, while drug-label annotations capture pharmacogenomic information included in regulatory product labels. Gene–drug associations connect pharmacogenes with medications and describe the available evidence. The resource also provides information about pharmacogenomic pathways, important pharmacogenes, allele definitions, and clinical prescribing recommendations. These different annotation types serve complementary purposes and should not be interpreted as equivalent levels of clinical evidence.
  • A major component of pharmacogenomic knowledgebases is the annotation of gene–drug relationships. A gene–drug relationship describes how variation in a gene may influence the response to a particular medication. For example, variation in CYP2C19 can influence the metabolism of clopidogrel, while variation in CYP2D6 can affect the metabolism of several medicines, including selected antidepressants and opioid analgesics. Variants in TPMT and NUDT15 can influence the risk of toxicity from thiopurine medicines, and variants in DPYD can affect the metabolism and toxicity risk of fluoropyrimidine drugs. These examples demonstrate how genetic differences in drug metabolism and transport can have important clinical implications.
  • Pharmacogenomic databases also distinguish between genotype, diplotype, phenotype, and clinical outcome. A genotype describes the genetic variants detected in an individual. A diplotype describes the combination of two haplotypes inherited on the corresponding chromosomes. A predicted phenotype describes the expected functional activity associated with the genotype, such as poor, intermediate, normal, rapid, or ultrarapid metabolizer status, depending on the gene and classification system. A clinical outcome refers to the observed response, toxicity, or treatment effectiveness. Genotype-to-phenotype translation is an interpretive process and may differ among genes, guidelines, and clinical contexts.
  • Many pharmacogenes are represented using the star allele nomenclature system. Star alleles, such as CYP2D61, CYP2D64, CYP2C192, and CYP2C1917, represent defined combinations of genetic variants associated with particular haplotypes. Different star alleles may produce normal, reduced, absent, or increased gene function. An individual’s diplotype is determined by the combination of alleles on the two homologous chromosomes, and this information may be used to infer a metabolizer phenotype. Accurate star allele assignment requires consideration of the relevant variants, their phase, gene structure, copy number, and the specific allele definitions used by the pharmacogenomic resource.
  • The Pharmacogene Variation Consortium (PharmVar) is a central resource for pharmacogene variation and standardized allele nomenclature. It provides curated information about haplotype structures, star allele definitions, defining variants, and related sequence information. PharmVar is particularly important for genes involved in drug metabolism and transport, including members of the cytochrome P450 family. It supports consistent naming of pharmacogenetic alleles across research studies, laboratories, databases, and clinical testing systems. Standardized allele definitions are essential because different laboratories must be able to describe the same pharmacogene haplotype consistently. <Cite refs={[“turn417995search0″,”turn417995search5”]}/>
  • The Clinical Pharmacogenetics Implementation Consortium (CPIC) develops evidence-based clinical practice guidelines that explain how available genetic test results can be used to guide medication prescribing. CPIC guidelines commonly focus on specific gene–drug pairs and provide recommendations based on genotype or predicted phenotype. They may address medication selection, dosage adjustment, monitoring, or alternative treatment options. CPIC’s primary purpose is to help clinicians use pharmacogenomic test results that are already available; whether a test should be ordered in a particular clinical situation is a separate decision that depends on local practice, clinical guidance, and healthcare policy. CPIC guidelines and supporting information are now accessible through the ClinPGx portal. <Cite refs={[“turn417995search1″,”turn417995search3”]}/>
  • The Dutch Pharmacogenetics Working Group (DPWG) is another important organization that develops clinical pharmacogenomic recommendations. It evaluates the effects of genetic variation on drug response and provides guidance on medication selection, dosage, and clinical monitoring. CPIC and DPWG recommendations may differ because they use different evidence assessments, clinical assumptions, and guideline development procedures. Researchers and healthcare professionals should therefore identify the source and version of the guideline being applied rather than combining recommendations without considering their context.
  • The Pharmacogenomic Clinical Annotation Tool (PharmCAT) supports the automated interpretation of pharmacogenomic genotypes. It processes genetic variant data, identifies relevant pharmacogene alleles or diplotypes, predicts phenotypes, and connects the results with applicable CPIC prescribing recommendations. PharmCAT can be incorporated into bioinformatics pipelines for analysing sequencing or genotyping data. It helps standardize the transformation of genetic test results into clinically relevant pharmacogenomic information. Its results depend on the quality and completeness of the input data, supported genes and alleles, and the guideline versions used. Complex loci and structural variation may require additional consideration or specialized methods. <Cite refs={[“turn417995search2″,”turn417995search6”]}/>
  • Regulatory agencies also provide important pharmacogenomic resources. The United States Food and Drug Administration (FDA) publishes a Table of Pharmacogenetic Associations containing information about genetic biomarkers included in certain drug labels. The table helps users identify medications for which pharmacogenomic information is described in FDA-approved prescribing information. However, the presence of a gene or biomarker in the table does not necessarily mean that FDA recommends genetic testing before prescribing the medicine. The wording and clinical implications must be assessed in the relevant drug label. Regulatory information should also be distinguished from clinical practice guidelines, which may provide more detailed genotype-specific recommendations.
  • The European Medicines Agency (EMA) provides regulatory information about medicines authorized in the European Union, including pharmacogenomic considerations where relevant. Product information may describe genetic biomarkers, contraindications, dosage considerations, or safety concerns associated with particular genotypes. National regulatory authorities and medicine information systems may provide additional guidance depending on the country. Pharmacogenomic databases can connect these regulatory documents with genetic evidence and clinical guidelines, but users should always consult the current official product information for the relevant medicine and jurisdiction.
  • Several other resources contribute to pharmacogenomic research and implementation. The Pharmacogenomics Global Research Network (PGRN) supports research collaboration, education, and the development of resources for pharmacogenomics. Its resource collections provide links to databases, analytical tools, guidelines, and research initiatives. The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) has developed resources and guidance related to adverse drug reactions and pharmacogenomic testing. These initiatives help expand the evidence base and support the translation of pharmacogenomic discoveries into healthcare practice.
  • DrugBank provides detailed information about drugs, including chemical structures, mechanisms of action, targets, pharmacokinetics, metabolism, and drug interactions. Its drug and protein information can help researchers connect pharmacogenomic findings with molecular mechanisms. ChEMBL provides bioactivity data for drug-like compounds and molecular targets, while PubChem supplies chemical information and identifiers that support the integration of drug-related datasets. These resources are not dedicated pharmacogenomic guideline databases, but they provide complementary information for investigating how genetic variation may affect drug targets, metabolism, and biological pathways.
  • The Pharmacogenomics Knowledgebase and related clinical resources also support the study of very important pharmacogenes, often abbreviated as VIPs. These are genes considered particularly relevant to drug response because of their effects on drug metabolism, transport, or pharmacological action. Examples include CYP2D6, CYP2C19, CYP2C9, CYP3A5, TPMT, NUDT15, DPYD, SLCO1B1, VKORC1, and HLA-B. The importance of a gene depends on the medications and clinical contexts being considered. VIP summaries provide background information about gene function, common variants, allele nomenclature, and relevant drug associations, helping researchers interpret pharmacogenomic evidence.
  • Pharmacogenomics databases support several important applications in bioinformatics. One major application is the identification of genetic variants associated with altered drug metabolism. Variants in genes encoding drug-metabolizing enzymes can change enzyme activity and therefore influence drug exposure. For example, reduced CYP2C19 activity can impair the conversion of clopidogrel into its active metabolite, while reduced CYP2D6 activity can alter the metabolism of medicines that depend on this enzyme. By combining genetic variant information with drug pathways and clinical annotations, researchers can investigate the molecular basis of variable drug response.
  • Another application is the identification of genetic variants associated with adverse drug reactions. Some individuals carry variants that increase their susceptibility to medication-related toxicity. For example, reduced TPMT or NUDT15 function can increase the risk of severe myelosuppression during thiopurine treatment. Certain HLA alleles are associated with serious immune-mediated reactions to specific medicines. HLA-B57:01 is associated with abacavir hypersensitivity, while HLA-B15:02 is associated with an increased risk of carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in susceptible populations. These examples demonstrate the importance of integrating pharmacogenomic evidence with medication-specific safety information.
  • Pharmacogenomics also supports individualized drug dosage. Standard doses may produce insufficient exposure in some individuals and excessive exposure in others because of genetic differences in drug metabolism or transport. Genotype-based recommendations can help identify patients who may require alternative doses or medications. Warfarin is a well-known example in which variation in CYP2C9 and VKORC1 can influence dose requirements, although clinical dosing also depends on factors such as age, diet, interacting medicines, and measured international normalized ratio (INR). Genetic information should therefore be integrated with clinical variables rather than used as the sole determinant of dosage.
  • Another important application is drug selection and therapeutic optimization. Genetic variation can influence whether a medication is likely to be effective or safe for a particular patient. Pharmacogenomic resources connect genetic markers with drug response evidence and clinical recommendations, helping identify situations in which an alternative medicine may be appropriate. This approach is particularly relevant in oncology, psychiatry, cardiovascular medicine, infectious diseases, and pain management. However, the strength of evidence varies between gene–drug pairs, and not every pharmacogenomic association has an established clinical recommendation.
  • Pharmacogenomic databases are also useful in drug discovery and development. Researchers can investigate how genetic variation affects drug targets, metabolic enzymes, transporters, and signalling pathways. Genetic differences may explain variation in treatment response observed during clinical trials and can help identify subgroups that respond differently to a drug. Pharmacogenomic information can also support the development of companion diagnostics and the design of clinical studies that account for genetic variability. Integrating genomic data with pharmacokinetic and pharmacodynamic measurements provides a more detailed understanding of drug action.
  • The analysis of pharmacogenomic data requires specialized bioinformatics methods. Genotyping arrays, targeted sequencing, whole-exome sequencing, and whole-genome sequencing can be used to identify relevant genetic variants. Variant calling is followed by quality control, normalization, annotation, haplotype reconstruction, and genotype-to-phenotype translation. Tools must account for complex gene regions, copy-number variation, gene deletions, duplications, hybrid genes, and highly similar pseudogenes. These challenges are particularly important for pharmacogenes such as CYP2D6, where structural variation and gene conversion can complicate genotype assignment.
  • Pharmacogenomic data are represented using several types of identifiers and formats. Genetic variants may be described using genomic coordinates, reference and alternate alleles, transcript-level descriptions, or HGVS nomenclature. Star alleles are used to describe pharmacogene haplotypes, while diplotypes represent combinations of alleles. Drug identifiers may be obtained from resources such as DrugBank, PubChem, or other controlled vocabularies. Standardized gene symbols, variant identifiers, allele definitions, and drug identifiers are essential for integrating information across databases. Researchers should record the reference genome assembly, transcript version, pharmacogene allele definition, and guideline release used in an analysis.
  • ClinPGx supports web-based searching, curated data access, downloadable datasets, and programmatic access through its API and data services. Researchers can retrieve clinical annotations, variant annotations, drug-label information, gene–drug associations, and other pharmacogenomic records for analysis. Bulk downloads are useful for large-scale research, while APIs support automated retrieval and integration into reproducible pipelines. Because PharmGKB was succeeded by ClinPGx, new workflows should use the current ClinPGx portal and API endpoints rather than relying on outdated standalone PharmGKB URLs. Database release information, retrieval dates, and licensing terms should be recorded. <Cite refs={[“turn417995search2″,”turn417995search10”]}/>
  • Despite their value, pharmacogenomics databases have several limitations. The strength of evidence varies among gene–drug associations, and many reported relationships have not been validated sufficiently for clinical implementation. Studies may differ in sample size, ancestry representation, drug exposure, clinical endpoints, and analytical methods. A genetic association observed in one population may not have the same predictive value in another population because allele frequencies, linkage disequilibrium patterns, and environmental factors differ. Many pharmacogenomic studies have historically underrepresented some global populations, limiting the generalizability of certain findings.
  • Another challenge is the complexity of translating genotype into phenotype. Different variants within a gene may have different functional effects, and some haplotypes contain multiple variants whose combined effect must be considered. Phase information is important because variants on the same chromosome may form one haplotype, while variants on different chromosomes may form a different diplotype. Copy-number variation and structural rearrangements can further complicate interpretation. In addition, phenotype classification systems and allele function assignments may be updated as new evidence becomes available. Bioinformatics pipelines must therefore use current definitions and document the versions applied.
  • Clinical recommendations may also differ among CPIC, DPWG, regulatory agencies, and national healthcare systems. One organization may recommend an alternative drug, while another may emphasize dose adjustment or monitoring. Such differences do not necessarily indicate that one resource is incorrect; they may reflect different evidence assessments, healthcare settings, or implementation policies. Researchers should examine the guideline’s scope, publication date, evidence strength, and intended clinical use. They should also distinguish between evidence that a genetic variant affects drug response and evidence that testing improves patient outcomes.
  • Pharmacogenomic information must be interpreted alongside non-genetic factors. Drug interactions, kidney and liver function, age, pregnancy, disease severity, adherence, diet, and environmental exposures can influence medication response. A genotype-based prediction is therefore not a complete description of an individual’s drug response. Pharmacogenomic test results should be reviewed by qualified healthcare professionals and interpreted using current clinical guidance. Database annotations are research and decision-support resources, not independent instructions for changing medication or dosage.
  • Reproducible pharmacogenomic analysis requires careful documentation of the database and guideline versions, reference genome assembly, variant-calling software, star allele definitions, phenotype translation method, and drug annotation sources. Researchers should preserve the original variant calls and intermediate haplotype assignments, particularly when complex pharmacogenes are involved. They should also document the evidence level associated with each gene–drug relationship and distinguish curated clinical recommendations from experimental associations or computational predictions. This information is essential for comparing results across laboratories and maintaining reliable pharmacogenomic workflows.
  • Overall, PharmGKB and related pharmacogenomics resources provide essential infrastructure for studying the influence of genetic variation on drug response. ClinPGx now serves as the integrated successor to the standalone PharmGKB portal, bringing together pharmacogenomic knowledge, CPIC guidelines, and PharmCAT-related resources. PharmVar provides standardized pharmacogene allele definitions, while DPWG, FDA, EMA, PGRN, and other organizations contribute complementary clinical, regulatory, and research information. Together, these resources support drug-response analysis, adverse reaction prediction, genotype-based prescribing, pharmacogenomic testing, drug development, and precision medicine. Their effective use depends on understanding evidence quality, allele nomenclature, genotype-to-phenotype translation, clinical context, population diversity, and the limitations of current knowledge.
Author:

Leave a Reply

Your email address will not be published. Required fields are marked *